BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27481651)

  • 21. Precision medicine for metastatic breast cancer.
    Deluche E; Onesti E; Andre F
    Am Soc Clin Oncol Educ Book; 2015; ():e2-7. PubMed ID: 25993174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapeutic options on the horizon in breast cancer treatment.
    van Rooijen JM; Stutvoet TS; Schröder CP; de Vries EG
    Pharmacol Ther; 2015 Dec; 156():90-101. PubMed ID: 26388292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precision Medicine in Breast Cancer.
    Odle TG
    Radiol Technol; 2017 Mar; 88(4):401M-421M. PubMed ID: 28298516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
    Ayoub NM; Al-Shami KM; Yaghan RJ
    Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene.
    Savas P; Caramia F; Teo ZL; Loi S
    Curr Opin Oncol; 2014 Nov; 26(6):562-7. PubMed ID: 25188474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomics of adjuvant therapy for breast cancer.
    Kim SR; Paik S
    Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Precision Medicine in Breast Cancer.
    Sachdev JC; Sandoval AC; Jahanzeb M
    Cancer Treat Res; 2019; 178():45-80. PubMed ID: 31209841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
    Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
    PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group.
    Geiersbach KB; Chen H; Emmadi R; Haskell GT; Lu X; Liu YJ; Swisshelm K
    Cancer Genet; 2020 Jun; 244():11-20. PubMed ID: 32087595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic profiling of breast cancers.
    Curtis C
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):34-9. PubMed ID: 25502431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
    Yates LR
    Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
    Dieci MV; Griguolo G; Miglietta F; Guarneri V
    Cancer Treat Rev; 2016 May; 46():9-19. PubMed ID: 27055087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
    Andre F; Vicier C; Delaloge S
    Am Soc Clin Oncol Educ Book; 2014; ():e5-10. PubMed ID: 24857146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision medicine in breast cancer: reality or utopia?
    Bettaieb A; Paul C; Plenchette S; Shan J; Chouchane L; Ghiringhelli F
    J Transl Med; 2017 Jun; 15(1):139. PubMed ID: 28623955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune approaches to the treatment of breast cancer, around the corner?
    Criscitiello C; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Adamoli L; Goldhirsch A; Curigliano G
    Breast Cancer Res; 2014 Feb; 16(1):204. PubMed ID: 25774617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
    Gingras I; Azim HA; Ignatiadis M; Sotiriou C
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):372-82. PubMed ID: 26352893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immune system and inflammation in breast cancer.
    Jiang X; Shapiro DJ
    Mol Cell Endocrinol; 2014 Jan; 382(1):673-682. PubMed ID: 23791814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.